Most people hear “Melanotan” and think of a tan.
The story started with a more ambitious question: could researchers stimulate the skin’s protective pigment before someone stepped into the sun?
That question helped launch the research behind Melanotan I and Melanotan II—usually shortened to MT1 and MT2. Along the way, scientists found effects that reached beyond skin color, and the two compounds took different paths.
The original idea: help skin prepare for sunlight
At the University of Arizona, researchers explored synthetic versions of alpha-melanocyte-stimulating hormone, or alpha-MSH. This natural signaling molecule helps regulate pigmentation.
The goal was to develop compounds with stronger, longer-lasting activity. A landmark paper describing the analogue later known as Melanotan I appeared in 1980. Researchers including Victor Hruby and Mac Hadley helped build the scientific foundation for the work. [1]
The skin-cancer prevention rationale was straightforward: melanin contributes to the skin’s natural defenses against ultraviolet radiation. Stimulating that pigment before UV exposure might offer a way to increase protection. The university later described the original development of afamelanotide in precisely that context. [2]
This is where the “sunscreen peptide” story comes from.
But calling it a sunscreen skips an important distinction. The researchers were investigating biological photoprotection—changing the skin’s pigment response. They were not developing a conventional cream that filters UV at the skin’s surface. And a research goal of preventing skin cancer is not proof that a compound achieves it.
MT1: could pigmentation increase without sunbathing?
Melanotan I is also known as NDP-alpha-MSH and afamelanotide.
In a 1991 randomized, placebo-controlled study published in JAMA, researchers studied 28 men. Those receiving the synthetic melanotropin developed measurable skin darkening; those receiving placebo did not. Participants used high-potency sunscreen during the trial. [3]
That last detail matters. The experiment was not simply asking whether a peptide could make a day of sunbathing more productive. It investigated whether a chemical signal could produce tanning without relying on potentially harmful UV exposure.
It was an intriguing demonstration of human pigmentation biology. It was not a large, long-term trial showing fewer skin cancers.
MT2: a smaller molecule with unexpected effects
Melanotan II came from the same broader research into melanocortin signaling. It is a cyclic, seven-amino-acid analogue—a different molecular design from MT1. [4]
A small 1996 phase I pilot study involved just three male volunteers. Researchers observed increased pigmentation in two participants. They also recorded nausea, fatigue or sleepiness, yawning and stretching, and spontaneous erections. [4]
An experiment investigating pigmentation had revealed effects involving sexual function.
That does not make MT2 an established sexual-health treatment. It explains why the compound attracted interest beyond tanning—and why describing it as merely a stronger MT1 misses part of its history.
The pilot’s size also deserves attention: three volunteers can reveal signals worth investigating, but cannot establish broad safety or predictable results.
MT1 vs. MT2 at a glance
| Question | MT1 | MT2 |
|---|---|---|
| What is it? | An alpha-MSH analogue also known as afamelanotide | A distinct cyclic, seven-amino-acid alpha-MSH analogue |
| What put it on the map? | Research into pigmentation without UV exposure | Pigmentation research that also revealed sexual effects |
| What happened clinically? | Afamelanotide became the active ingredient in Scenesse | The early findings encouraged further melanocortin research |
| Is an online vial equivalent to an approved medicine? | No—approval applies to a specific product and indication | MT2 should not be confused with approved related medicines |
How the research is used today
A medical use for MT1’s molecule
Afamelanotide eventually became Scenesse, an implant administered by trained healthcare professionals. Its initial U.S. approval came in 2019.
The FDA indication is to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria, or EPP. This rare condition can make light exposure intensely painful. [5]
That is a meaningful medical application, but it is specific. Scenesse’s approval does not extend to every product labeled “MT1,” and does not establish an online research vial as an approved cosmetic tanning treatment.
Tanning outside approved medical care
Outside that medical setting, melanotan products are promoted for cosmetic tanning, including injections and nasal sprays. This is a description of how they are marketed and used, not an established safe-use protocol. [6]
Product consistency adds another uncertainty. In August 2026, Australia’s TGA reported testing five MT2 nasal-spray bottles labeled 30 mg; estimated amounts ranged from 22 mg to 54 mg. That finding concerns those tested products, not every seller, but illustrates why a label alone cannot establish what a user receives. [7]
A connection to sexual-function research
The sexual effects observed in early melanocortin research helped make this signaling system a subject of further investigation. A 2003 clinical paper examined PT-141, now known as bremelanotide, for sexual dysfunction. [8]
Bremelanotide is the active ingredient in Vyleesi, a separate prescription medicine approved for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder. Vyleesi is not MT2, and its approval is not approval of MT2 for libido, erectile dysfunction or sexual performance. [9]
Does a peptide-induced tan replace sunscreen?
No. Increased pigmentation should not be treated as permission to increase UV exposure or skip sunscreen, clothing and shade. The TGA specifically cautions that melanotan-induced pigmentation does not provide the protection of a suitable sunscreen. [6]
The “originally sunscreen” history is therefore best told this way: researchers wanted to investigate whether stimulating natural pigmentation could improve photoprotection. That scientific ambition never established MT1 or MT2 as a substitute for everyday sun protection.
The history is more interesting than the nickname
MT1 and MT2 connect several scientific stories: pigment biology, the search for protection from sunlight, a rare light-sensitivity disorder, and unexpected findings involving sexual function.
Their shared origin helps explain why people group them together. Their different development paths explain why they should be understood separately.
A deeper tan was the visible result. The research behind it reached much further.
Sources
1. Sawyer et al. (1980), foundational NDP-alpha-MSH research: https://pmc.ncbi.nlm.nih.gov/articles/PMC350149/
2. University of Arizona, original skin-cancer prevention rationale and afamelanotide history: https://cancercenter.arizona.edu/news/2014/10/ua-discovered-drug-skin-disease-approved-patients-europe
3. Levine et al. (1991), controlled human pigmentation study: https://pubmed.ncbi.nlm.nih.gov/1658407/
4. Dorr et al. (1996), MT2 phase I pilot: https://pubmed.ncbi.nlm.nih.gov/8637402/
5. FDA, Scenesse prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007lbl.pdf
6. TGA, melanotan products and sun-protection warning: https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan
7. TGA (August 17, 2026), testing of MT2 nasal sprays: https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/melanotan-ii-tanning-peptide-products-found-be-inconsistently-dosed
8. Molinoff et al. (2003), PT-141 clinical research: https://pubmed.ncbi.nlm.nih.gov/12851303/
9. FDA, Vyleesi prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005lbl.pdf